Literature DB >> 9850152

ISCOMs: an adjuvant with multiple functions.

A Sjölander1, J C Cox, I G Barr.   

Abstract

Aluminum salts are currently the only widely used adjuvant for human vaccines. Over the past 10-15 years, a large research effort has attempted to find novel adjuvants with ability to induce a broad range of immune responses, including cell-mediated immunity. The immunostimulating complex or ISCOM is one adjuvant with multiple adjuvant properties. ISCOMs are open cage-like complexes typically with a diameter of about 40 nm that are built up by cholesterol, lipid, immunogen, and saponins from the bark of the tree Quillaia saponaria Molina. ISCOMs have been demonstrated to promote antibody responses and induce T helper cell as well as cytotoxic T lymphocyte responses in a variety of experimental animal models, and have now progressed to phase I and II human trials. This review describes recent developments in the understanding of the structure, composition, and preparation of ISCOMs and will cover important aspects of the understanding of the adjuvant functions of ISCOMs and how they act on the immune system.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9850152     DOI: 10.1002/jlb.64.6.713

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  14 in total

1.  Mimovirus: a novel form of vaccine that induces hepatitis B virus-specific cytotoxic T-lymphocyte responses in vivo.

Authors:  Yu-Zhang Wu; Jian-Ping Zhao; Ying Wan; Zheng-Cai Jia; Wei Zhou; Jiang Bian; Bing Ni; Li-Yun Zou; Yan Tang
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

2.  Archaeosome vaccine adjuvants induce strong humoral, cell-mediated, and memory responses: comparison to conventional liposomes and alum.

Authors:  L Krishnan; C J Dicaire; G B Patel; G D Sprott
Journal:  Infect Immun       Date:  2000-01       Impact factor: 3.441

3.  Vaccine adjuvants - Current status and prospects on controlled release adjuvancity.

Authors:  S M Sivakumar; Mohammed M Safhi; M Kannadasan; N Sukumaran
Journal:  Saudi Pharm J       Date:  2011-06-25       Impact factor: 4.330

4.  RD antigen based nanovaccine imparts long term protection by inducing memory response against experimental murine tuberculosis.

Authors:  Mairaj Ahmed Ansari; Swaleha Zubair; Anjum Mahmood; Pushpa Gupta; Aijaz A Khan; Umesh D Gupta; Ashish Arora; Mohammad Owais
Journal:  PLoS One       Date:  2011-08-11       Impact factor: 3.240

5.  Tubular immunostimulating complex based on cucumarioside A2-2 and monogalactosyldiacylglycerol from marine macrophytes.

Authors:  Eduard Y Kostetsky; Nina M Sanina; Andrey N Mazeika; Alexander V Tsybulsky; Natalia S Vorobyeva; Valery L Shnyrov
Journal:  J Nanobiotechnology       Date:  2011-09-02       Impact factor: 10.435

6.  The role of ISCOMATRIX bilayer composition to induce a cell mediated immunity and protection against leishmaniasis in BALB/c mice.

Authors:  Ahmad Mehravaran; Mahmoud Reza Jaafari; Seyed Amir Jalali; Ali Khamesipour; Reza Ranjbar; Mansure Hojatizade; Ali Badiee
Journal:  Iran J Basic Med Sci       Date:  2016-02       Impact factor: 2.699

7.  Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model.

Authors:  Gabriel Pedersen; Diane Major; Sarah Roseby; John Wood; Abdullah S Madhun; Rebecca J Cox
Journal:  Influenza Other Respir Viruses       Date:  2011-05-09       Impact factor: 4.380

8.  Fast antibody responses by immuno-targeting and nanotechnology strategies versus HBsAg vaccine.

Authors:  Mahsa Rezaei; Seyed Nezamedin Hosseini; Ramazan Ali Khavari-Nejad; Farhood Najafi; Mehdi Mahdavi
Journal:  Iran J Basic Med Sci       Date:  2021-04       Impact factor: 2.699

Review 9.  A Systematic Review of Recent Advances in Equine Influenza Vaccination.

Authors:  Romain Paillot
Journal:  Vaccines (Basel)       Date:  2014-11-14

Review 10.  Metabolic and functional diversity of saponins, biosynthetic intermediates and semi-synthetic derivatives.

Authors:  Tessa Moses; Kalliope K Papadopoulou; Anne Osbourn
Journal:  Crit Rev Biochem Mol Biol       Date:  2014-10-06       Impact factor: 8.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.